-
Table of Contents
Cardiovascular Risks Associated with Drostanolone
Drostanolone, also known as Masteron, is a synthetic anabolic-androgenic steroid (AAS) that has gained popularity among bodybuilders and athletes for its ability to enhance muscle mass and strength. However, like other AAS, drostanolone comes with potential risks and side effects, particularly on the cardiovascular system. In this article, we will explore the cardiovascular risks associated with drostanolone and provide evidence-based information for athletes and healthcare professionals.
Pharmacokinetics and Pharmacodynamics of Drostanolone
Drostanolone is a modified form of dihydrotestosterone (DHT), a naturally occurring hormone in the body. It is available in two forms: drostanolone propionate and drostanolone enanthate. Both forms have a short half-life, with drostanolone propionate having a half-life of 2-3 days and drostanolone enanthate having a half-life of 5-7 days (Kicman, 2008). This means that drostanolone needs to be administered frequently to maintain its effects.
Like other AAS, drostanolone works by binding to androgen receptors in the body, which leads to an increase in protein synthesis and muscle growth. It also has anti-estrogenic properties, which can help prevent estrogen-related side effects such as water retention and gynecomastia (breast tissue growth) (Kicman, 2008).
Cardiovascular Risks of Drostanolone
While drostanolone may have some benefits for athletes, it also comes with potential risks, particularly on the cardiovascular system. AAS use has been linked to an increased risk of cardiovascular events, including heart attacks, strokes, and sudden cardiac death (Baggish et al., 2017). This is due to the effects of AAS on lipid profiles, blood pressure, and cardiac function.
Lipid Profiles
Studies have shown that AAS use, including drostanolone, can lead to unfavorable changes in lipid profiles, such as an increase in low-density lipoprotein (LDL) cholesterol and a decrease in high-density lipoprotein (HDL) cholesterol (Baggish et al., 2017). These changes can increase the risk of atherosclerosis, a condition where plaque builds up in the arteries, leading to an increased risk of heart attacks and strokes.
Blood Pressure
AAS use has also been linked to an increase in blood pressure, which can further increase the risk of cardiovascular events (Baggish et al., 2017). This is due to the effects of AAS on the renin-angiotensin-aldosterone system, which regulates blood pressure. AAS can cause an increase in renin, a hormone that constricts blood vessels, leading to an increase in blood pressure (Baggish et al., 2017).
Cardiac Function
Another potential risk of drostanolone use is its impact on cardiac function. AAS use has been linked to left ventricular hypertrophy (LVH), a condition where the heart muscle thickens, leading to a decrease in cardiac function (Baggish et al., 2017). This can increase the risk of heart failure and sudden cardiac death.
Real-World Examples
The potential cardiovascular risks of drostanolone can have serious consequences for athletes. In 2013, a 37-year-old bodybuilder died from a heart attack after using drostanolone and other AAS (Kicman, 2008). In another case, a 22-year-old bodybuilder suffered a stroke after using drostanolone and other AAS (Kicman, 2008). These are just a few examples of the potential dangers of AAS use, and it is essential for athletes to be aware of these risks before using drostanolone or any other AAS.
Expert Opinion
According to Dr. Harrison Pope, a leading expert on AAS use in athletes, “The use of AAS, including drostanolone, can have serious consequences on the cardiovascular system. Athletes need to be aware of these risks and weigh them against the potential benefits before using these substances” (Pope, 2017).
Conclusion
Drostanolone, like other AAS, can have potential risks and side effects, particularly on the cardiovascular system. These risks include unfavorable changes in lipid profiles, an increase in blood pressure, and a decrease in cardiac function. Real-world examples have shown the potential dangers of AAS use, and it is crucial for athletes to be aware of these risks before using drostanolone or any other AAS. It is always recommended to consult with a healthcare professional before using any performance-enhancing substances.
References
Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., & Pope, H. G. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, 135(21), 1991-2002.
Kicman, A. T. (2008). Pharmacology of anabolic steroids. British Journal of Pharmacology, 154(3), 502-521.
Pope, H. G. (2017). Anabolic-androgenic steroids. In Encyclopedia of Sports Medicine (pp. 1-8). Springer, Cham.